On September 20, 2024, the Food and Drug Administration sanctioned isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) in conjunction with bortezomib, lenalidomide, and dexamethasone for people with...
On September 19, 2024, the Food and Drug Administration sanctioned amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in conjunction with carboplatin and pemetrexed for adult patients diagnosed with ...
On September 17, 2024, the Food and Drug Administration authorized pembrolizumab (Keytruda, Merck) in conjunction with pemetrexed and platinum-based chemotherapy as the initial treatment for unresec...
On September 17, 2024, the Food and Drug Administration approved ribociclib (Kisqali, Novartis Pharmaceuticals Corporation) in conjunction with an aromatase inhibitor for the adjuvant therapy of adult...
On September 12, 2024, the Food and Drug Administration sanctioned atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous administration for all adult indications co...
CAR T Cell therapy in KoreaCAR T cell therapy is an advanced cancer treatment that has gained significant momentum in South Korea. It involves genetically modifying a patient’s T cells to recognize ...
In the constantly shifting field of therapy for cancer, Gamma Delta T Cell therapy presents itself as the new hope treatment. Known primarily for its efficacy in using one's own body's immune system t...
August 2024: Vorasidenib (Voranigo, Servier Pharmaceuticals LLC), an inhibitor of isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2), has been approved by the Food and Drug Admini...
August 2024: The Food and Drug Administration has given accelerated approval to afamitresgene autoleucel (TECELRA, Adaptimmune, LLC), a genetically modified autologous T cell immunotherapy that target...
August 2024: The Food and Drug Administration has granted approval for dostarlimab-gxly (Jemperli, GSK) in combination with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for t...